Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
To ensure favorable drug-like properties, we integrated developability assessment from the outset using our proprietary AlfaDAX platform, which predicts key biophysical and biochemical liabilities including isoelectric point (pI), humanization score (Hu), immunogenicity risk (Immu), aggregation propensity (AP), viscosity risk (Vis), and non-specific binding (NSB)
Use is especially high among adults ages 50 to 64 and among individuals with diabetes, heart disease, or obesity
In Part II we will focus on the twincretins GIP and GLP-1 [3] to improve glycemic control and the tri-agonists GLP-1/GIP/Glucagon to treat obesity, type 2 diabetes mellitus and hepatosteatosis [non-alcoholic steatohepatitis (NASH)]
Management strategies include maintaining excellent oral hygiene, staying well-hydrated throughout the day, stimulating saliva flow with sugar-free gum or candies, using alcohol-free mouthwash, and addressing potential gastroesophageal reflux
Warnings There are some known risks stated in the prescribing information for these drugs
US$ 26.97
US$ 20.18
US$ 24.87
US$ 21.97
US$ 23.20
US$ 23.45
US$ 21.91
US$ 28.50
US$ 28.90
US$ 24.79
US$ 27.86
US$ 23.57
US$ 21.89
